{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:04:25Z","timestamp":1792555465525,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22376016, 22022601"],"award-info":[{"award-number":["22376016, 22022601"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171982"],"award-info":[{"award-number":["82171982"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2023J06031"],"award-info":[{"award-number":["2023J06031"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Joint Funds for the Innovation of Science and Technology, Fujian Province","award":["2024Y9138"],"award-info":[{"award-number":["2024Y9138"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00259-025-07591-7","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:37:48Z","timestamp":1761097068000},"page":"2489-2501","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Preclinical evaluation and first-in-human study of 68Ga- and Al18F-Labeled PSMA\/FAP bispecific tracers for prostate cancer imaging"],"prefix":"10.1007","volume":"53","author":[{"given":"Xinlin","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruotong","family":"Jian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haonan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaobo","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3488-7864","authenticated-orcid":false,"given":"Mengchao","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"7591_CR1","doi-asserted-by":"publisher","first-page":"79S","DOI":"10.2967\/jnumed.115.170720","volume":"57","author":"A Afshar-Oromieh","year":"2016","unstructured":"Afshar-Oromieh A, Babich JW, Kratochwil C, et al. The rise of PSMA ligands for diagnosis and therapy of prostate cancer. J Nucl Med. 2016;57:79S. https:\/\/doi.org\/10.2967\/jnumed.115.170720.","journal-title":"J Nucl Med"},{"key":"7591_CR2","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","volume":"44","author":"FL Giesel","year":"2017","unstructured":"Giesel FL, Hadaschik B, Cardinale J, et al. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2017;44:678\u201388. https:\/\/doi.org\/10.1007\/s00259-016-3573-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7591_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","volume":"42","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42:197\u2013209. https:\/\/doi.org\/10.1007\/s00259-014-2949-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7591_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2021.03.004","volume":"80","author":"MS Sadaghiani","year":"2021","unstructured":"Sadaghiani MS, Sheikhbahaei S, Werner RA, et al. A systematic review and meta-analysis of the effectiveness and toxicities of Lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer. Eur Urol. 2021;80:82\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2021.03.004.","journal-title":"Eur Urol"},{"key":"7591_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.796657","volume":"12","author":"J Ma","year":"2022","unstructured":"Ma J, Li L, Liao T, et al. Efficacy and safety of (225)Ac-PSMA-617-targeted alpha therapy in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Front Oncol. 2022;12:796657. https:\/\/doi.org\/10.3389\/fonc.2022.796657.","journal-title":"Front Oncol"},{"key":"7591_CR6","doi-asserted-by":"publisher","first-page":"546","DOI":"10.2967\/jnumed.119.231654","volume":"61","author":"H Song","year":"2020","unstructured":"Song H, Harrison C, Duan H, et al. Prospective evaluation of (18)F-DCFPyL PET\/CT in biochemically recurrent prostate cancer in an academic center: a focus on disease localization and changes in management. J Nucl Med. 2020;61:546\u201351. https:\/\/doi.org\/10.2967\/jnumed.119.231654.","journal-title":"J Nucl Med"},{"issue":"4","key":"7591_CR7","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nrurol.2016.26","volume":"13","author":"T Maurer","year":"2016","unstructured":"Maurer T, Eiber M, Schwaiger M, et al. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 2016;13(4):226\u201335. https:\/\/doi.org\/10.1038\/nrurol.2016.26.","journal-title":"Nat Rev Urol"},{"key":"7591_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/1544208","volume":"2021","author":"S McGeorge","year":"2021","unstructured":"McGeorge S, Kwok M, Jiang A, et al. Dual-tracer positron-emission tomography using prostate-specific membrane antigen and fluorodeoxyglucose for staging of prostate cancer: a systematic review. Adv Urol. 2021;1544208. https:\/\/doi.org\/10.1155\/2021\/1544208.","journal-title":"Adv Urol"},{"key":"7591_CR9","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","volume":"76","author":"A Paschalis","year":"2019","unstructured":"Paschalis A, Sheehan B, Riisnaes R, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76:469\u201378. https:\/\/doi.org\/10.1016\/j.eururo.2019.06.030.","journal-title":"Eur Urol"},{"key":"7591_CR10","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Flechsig P, Lindner T, et al. (68)Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60:801\u20135. https:\/\/doi.org\/10.2967\/jnumed.119.227967.","journal-title":"J Nucl Med"},{"key":"7591_CR11","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1007\/s00259-019-04623-x","volume":"47","author":"F Khreish","year":"2020","unstructured":"Khreish F, Rosar F, Kratochwil C, et al. Positive FAPI-PET\/CT in a metastatic castration-resistant prostate cancer patient with PSMA-negative\/FDG-positive disease. Eur J Nucl Med Mol Imaging. 2020;47:2040\u20131. https:\/\/doi.org\/10.1007\/s00259-019-04623-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7591_CR12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00259-021-05423-y","volume":"49","author":"C Kesch","year":"2021","unstructured":"Kesch C, Yirga L, Dendl K, et al. High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics. Eur J Nucl Med Mol Imaging. 2021;49:385\u20139. https:\/\/doi.org\/10.1007\/s00259-021-05423-y.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7591_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/genes13010135","volume":"13","author":"PJ Vlachostergios","year":"2022","unstructured":"Vlachostergios PJ, Karathanasis A, Tzortzis V. Expression of fibroblast activation protein is enriched in neuroendocrine prostate cancer and predicts worse survival. Genes. 2022;13:135. https:\/\/doi.org\/10.3390\/genes13010135.","journal-title":"Genes"},{"key":"7591_CR14","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1021\/acs.molpharmaceut.2c01000","volume":"20","author":"P Wang","year":"2023","unstructured":"Wang P, Wang S, Liu F, et al. Preclinical evaluation of a fibroblast activation protein and a prostate-specific membrane antigen dual-targeted probe for noninvasive prostate cancer imaging. Mol Pharm. 2023;20:1415\u201325. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c01000.","journal-title":"Mol Pharm"},{"key":"7591_CR15","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.1007\/s00259-022-05933-3","volume":"49","author":"S Boinapally","year":"2022","unstructured":"Boinapally S, Lisok A, Lofland G, et al. Hetero-bivalent agents targeting FAP and PSMA. Eur J Nucl Med Mol Imaging. 2022;49:4369\u201381. https:\/\/doi.org\/10.1007\/s00259-022-05933-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7591_CR16","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.7150\/thno.108676","volume":"15","author":"Y Li","year":"2025","unstructured":"Li Y, Guan L, Zhang X, et al. Dual targeting PET tracer [(68)Ga]Ga-PSFA-01 in patients with prostate cancers: a pilot exploratory study. Theranostics. 2025;15:4124\u201334. https:\/\/doi.org\/10.7150\/thno.108676.","journal-title":"Theranostics"},{"key":"7591_CR17","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1007\/s00259-024-06965-7","volume":"52","author":"X Wang","year":"2025","unstructured":"Wang X, Zhang X, Zhang X, et al. Design, preclinical evaluation, and first-in-human PET study of [(68)Ga]Ga-PSFA-01: a PSMA\/FAP heterobivalent tracer. Eur J Nucl Med Mol Imaging. 2025;52:1166\u201376. https:\/\/doi.org\/10.1007\/s00259-024-06965-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7591_CR18","doi-asserted-by":"publisher","first-page":"13332","DOI":"10.1021\/acs.jmedchem.3c01475","volume":"66","author":"Y Chen","year":"2023","unstructured":"Chen Y, Zhang X, Ni M, et al. Synthesis, preclinical evaluation, and first-in-human PET study of [(68)Ga]-labeled biphenyl-containing PSMA tracers. J Med Chem. 2023;66:13332\u201345. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c01475.","journal-title":"J Med Chem"},{"key":"7591_CR19","doi-asserted-by":"publisher","first-page":"12711","DOI":"10.1021\/ja104591m","volume":"132","author":"AX Zhang","year":"2010","unstructured":"Zhang AX, Murelli RP, Barinka C, et al. A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules. J Am Chem Soc. 2010;132:12711\u20136. https:\/\/doi.org\/10.1021\/ja104591m.","journal-title":"J Am Chem Soc"},{"key":"7591_CR20","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1007\/s00259-021-05486-x","volume":"49","author":"X Duan","year":"2022","unstructured":"Duan X, Cao Z, Zhu H, et al. 68Ga-labeled ODAP-Urea-based PSMA agents in prostate cancer: first-in-human imaging of an optimized agent. Eur J Nucl Med Mol Imaging. 2022;49:1030\u201340. https:\/\/doi.org\/10.1007\/s00259-021-05486-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7591_CR21","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.2967\/jnumed.120.258434","volume":"62","author":"M Suh","year":"2021","unstructured":"Suh M, Im HJ, Ryoo HG, et al. Head-to-head comparison of (68)Ga-NOTA ((68)Ga-NGUL) and (68)Ga-PSMA-11 in patients with metastatic prostate cancer: a prospective study. J Nucl Med. 2021;62:1457\u201360. https:\/\/doi.org\/10.2967\/jnumed.120.258434.","journal-title":"J Nucl Med"},{"key":"7591_CR22","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.apsb.2021.09.032","volume":"12","author":"K Hu","year":"2022","unstructured":"Hu K, Li J, Wang L, et al. Preclinical evaluation and pilot clinical study of [(18)F]AlF-labeled FAPI-tracer for PET imaging of cancer associated fibroblasts. Acta Pharm Sin B. 2022;12:867\u201375. https:\/\/doi.org\/10.1016\/j.apsb.2021.09.032.","journal-title":"Acta Pharm Sin B"},{"issue":"3","key":"7591_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28031088","volume":"28","author":"A Verena","year":"2023","unstructured":"Verena A, Zhang Z, Kuo H-T, et al. Synthesis and preclinical evaluation of three novel (68)Ga-labeled bispecific PSMA\/FAP-targeting tracers for prostate cancer imaging. Molecules. 2023;28(3):1088. https:\/\/doi.org\/10.3390\/molecules28031088.","journal-title":"Molecules"},{"key":"7591_CR24","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1097\/rlu.0000000000002354","volume":"44","author":"E Panagiotidis","year":"2019","unstructured":"Panagiotidis E, Paschali A, Giannoula E, et al. Rib fractures mimicking bone metastases in 18F-PSMA-1007 PET\/CT for prostate cancer. Clin Nucl Med. 2019;44:e46\u20138. https:\/\/doi.org\/10.1097\/rlu.0000000000002354.","journal-title":"Clin Nucl Med"},{"key":"7591_CR25","doi-asserted-by":"publisher","first-page":"729","DOI":"10.2967\/jnumed.119.234898","volume":"61","author":"F Dietlein","year":"2020","unstructured":"Dietlein F, Kobe C, Hohberg M, et al. Intraindividual comparison of (18)F-PSMA-1007 with renally excreted PSMA ligands for PSMA PET imaging in patients with relapsed prostate cancer. J Nucl Med. 2020;61:729\u201334. https:\/\/doi.org\/10.2967\/jnumed.119.234898.","journal-title":"J Nucl Med"},{"issue":"6","key":"7591_CR26","doi-asserted-by":"publisher","first-page":"6832","DOI":"10.1021\/acs.jmedchem.5c00401","volume":"68","author":"Y Chen","year":"2025","unstructured":"Chen Y, Ni M, Zhang X, et al. Preclinical evaluation and first-in-human PET study of Al(18)F-labeled biphenyl-based dimeric PSMA tracers. J Med Chem. 2025;68(6):6832\u201343. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c00401.","journal-title":"J Med Chem"},{"key":"7591_CR27","doi-asserted-by":"publisher","first-page":"862","DOI":"10.2967\/jnumed.121.263016","volume":"63","author":"L Zhao","year":"2022","unstructured":"Zhao L, Niu B, Fang J, et al. Synthesis, preclinical evaluation, and a pilot clinical PET imaging study of (68)Ga-labeled FAPI dimer. J Nucl Med. 2022;63:862\u20138. https:\/\/doi.org\/10.2967\/jnumed.121.263016.","journal-title":"J Nucl Med"},{"key":"7591_CR28","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2967\/jnumed.123.266183","volume":"65","author":"L Zhao","year":"2024","unstructured":"Zhao L, Pang Y, Fang J, et al. Design, preclinical evaluation, and clinical translation of (68)Ga-FAPI-LM3, a heterobivalent molecule for PET imaging of nasopharyngeal carcinoma. J Nucl Med. 2024;65:394\u2013401. https:\/\/doi.org\/10.2967\/jnumed.123.266183.","journal-title":"J Nucl Med"},{"key":"7591_CR29","doi-asserted-by":"publisher","DOI":"10.7150\/thno.113070","author":"H Gao","year":"2025","unstructured":"Gao H, Ma Z, Zhu Z, et al. [(18)F]FDG\/[(18)F]AlF-NOTA-FAPI-04 PET\/CT in renal cell carcinoma. Theranostics. 2025;15:5790\u2013800. https:\/\/doi.org\/10.7150\/thno.113070. Comparative study of [(18)F]AlF-NOTA-FAPI-RGD."},{"key":"7591_CR30","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1021\/acsmedchemlett.4c00324","volume":"15","author":"C Liolios","year":"2024","unstructured":"Liolios C, Bouziotis D, Sihver W, et al. Synthesis and preclinical evaluation of a bispecific PSMA-617\/RM2 heterodimer targeting prostate cancer. ACS Med Chem Lett. 2024;15:1970\u20138. https:\/\/doi.org\/10.1021\/acsmedchemlett.4c00324.","journal-title":"ACS Med Chem Lett"},{"key":"7591_CR31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1021\/bc4005377","volume":"25","author":"HM Shallal","year":"2014","unstructured":"Shallal HM, Minn I, Banerjee SR, et al. Heterobivalent agents targeting PSMA and Integrin-\u03b1v\u03b23. Bioconjug Chem. 2014;25:393\u2013405. https:\/\/doi.org\/10.1021\/bc4005377.","journal-title":"Bioconjug Chem"},{"key":"7591_CR32","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40644-020-00300-7","volume":"20","author":"F de Galiza Barbosa","year":"2020","unstructured":"de Galiza Barbosa F, Queiroz MA, Nunes RF, et al. Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findings. Cancer Imaging. 2020;20:23. https:\/\/doi.org\/10.1186\/s40644-020-00300-7.","journal-title":"Cancer Imaging"},{"key":"7591_CR33","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1007\/s00259-022-05758-0","volume":"49","author":"Y Wei","year":"2022","unstructured":"Wei Y, Zheng J, Ma L, et al. [18F]AlF-NOTA-FAPI-04: fap-targeting specificity, biodistribution, and PET\/CT imaging of various cancers. Eur J Nucl Med Mol Imaging. 2022;49:2761\u201373. https:\/\/doi.org\/10.1007\/s00259-022-05758-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7591_CR34","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1007\/s00259-025-07078-5","volume":"52","author":"PMA Waibel","year":"2025","unstructured":"Waibel PMA, Glavynskyi I, Fechter T, et al. Can PSMA PET detect intratumour heterogeneity in histological PSMA expression of primary prostate cancer? Analysis of [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007. Eur J Nucl Med Mol Imaging. 2025;52:2023\u201333. https:\/\/doi.org\/10.1007\/s00259-025-07078-5.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07591-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-025-07591-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-025-07591-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T18:02:51Z","timestamp":1771783371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-025-07591-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7591"],"URL":"https:\/\/doi.org\/10.1007\/s00259-025-07591-7","relation":{"references":[{"id-type":"doi","id":"10.7150\/thno.113070","asserted-by":"subject"}]},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The reported patients gave written informed consent to receive the diagnostics and permitted publication of his case and medical data under condition of anonymity.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"All animal studies were approved by the Institutional Animal Care and Use Committee of Beijing Normal University (BNUCC-EAW-2024-0909-02).The clinical study was approved by the Ethics Committee of Tianjin Medical University General Hospital and conducted in accordance with the Declaration of Helsinki. The trial is registered at ClinicalTrials.gov (NCT06690970).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"No other potential conflict of interest relevant to this article was reported.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}